Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inhaled vasodilators].

B Zwissler1

  • 1Klinik für Anästhesiologie der LMU München, Germany. Bernhard.Zwissler@ana.med.unimuencyen.de

Der Anaesthesist
|October 23, 2002
PubMed
Summary
This summary is machine-generated.

Inhaled nitric oxide (NO) and other vasodilators improve oxygenation and reduce pulmonary artery pressure. Despite limited formal outcome data, their clinical efficacy drives increasing off-label use in critical care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

German guidelines for airway management 2023.

Die Anaesthesiologie·2024
Same author

[Structured patient handover in high-risk areas : Evidence and recommendations for the practical implementation].

Die Anaesthesiologie·2023
Same author

[Advance Care Planning-further development of the patient advance directive : What the specialist in internal medicine must know].

Der Internist·2022
Same author

[Short version of the 2nd edition of the German-Austrian S3 guidelines "Cardiogenic shock complicating myocardial infarction-Diagnosis, monitoring and treatment"].

Der Anaesthesist·2020
Same author

Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patients compared to non-COVID-19 ARDS patients.

Thrombosis research·2020
Same author

[Publish via open access thanks to the DEAL agreement : Give your scientific articles the widest possible distribution].

Der Anaesthesist·2020
Same journal

[Promoting young academics in anesthesiology: factors for an attractive internship].

Der Anaesthesist·2022
Same journal

[Respiratory support in COVID-19: all in due time!]

Der Anaesthesist·2022
Same journal

[Noninvasive respiratory support and invasive ventilation in COVID‑19 : Where do we stand today?]

Der Anaesthesist·2022
Same journal

[Management of acutely decompensated liver cirrhosis in emergency and critical care medicine].

Der Anaesthesist·2022
Same journal

[Anesthesia in patients with acute porphyria].

Der Anaesthesist·2022
Same journal

[Quality and safe anesthesia for all children : That is their right!]

Der Anaesthesist·2022
See all related articles

Area of Science:

  • Pulmonary medicine
  • Pharmacology
  • Critical care

Background:

  • Inhaled nitric oxide (NO) selectively dilates pulmonary vessels, improving oxygenation and reducing pulmonary artery pressure.
  • Since 1991, studies have explored inhaled NO and other vasodilators for pulmonary hypertension and hypoxemia.
  • Primary pulmonary hypertension of the newborn (PPHN) is the sole approved indication for inhaled NO.

Purpose of the Study:

  • To review the pathophysiological and pharmacological basis of inhaled vasodilators.
  • To critically reevaluate potential clinical indications for inhaled vasodilators.
  • To provide a perspective on future developments in inhaled vasodilator therapy.

Main Methods:

  • Literature review of studies on inhaled vasodilators.

Related Experiment Videos

  • Analysis of pathophysiological and pharmacological data.
  • Critical evaluation of clinical efficacy and indications.

    • Main Results:

    • Inhaled NO demonstrates selective pulmonary vasodilation, improving oxygenation and decreasing pulmonary artery pressure.
    • Other aerosolized vasodilators like PGI(2), PGE(1), nitrates, and phosphodiesterase-inhibitors have also been studied.
    • Despite proven efficacy, formal documentation of improved patient outcomes is lacking for most inhaled vasodilator applications.

    Conclusions:

    • Inhaled vasodilators, particularly NO, show significant clinical efficacy in improving hemodynamic parameters and oxygenation.
    • The "off-label" use of inhaled vasodilators is increasing in anesthesia and intensive care medicine globally.
    • Further research is needed to formally document clinical benefits and expand approved indications for inhaled vasodilators.